CD19 NEX-T (BMS-986353) Next-Generation Chimeric Antigen Receptor (CAR) T Cell Therapy in Severe Refractory Autoimmune Diseases
- Leveraging extensive CAR T cell manufacturing experience to establish the nextgeneration NEX-T manufacturing process
- Assessing the pharmacokinetics and pharmacodynamics of NEX-T CAR T cell therapy in a diverse patient population
- Establishing pooled safety and preliminary efficacy of NEX-T CAR T cell therapy in severe refractory autoimmune diseases